AstraZeneca PLC (LON:0A4J)
London
· Delayed Price · Currency is GBP · Price in USD 82.89
-1.66 (-1.96%)
At close: Oct 29, 2025
Revenue
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| Oncology Revenue | 23.93B | 20.28B |
Log In |
Log In |
Log In | Upgrade
|
| BioPharmaceuticals: CVRM Revenue | 12.86B | 12.45B |
Log In |
Log In |
Log In | Upgrade
|
| BioPharmaceuticals: R&I Revenue | 8.48B | 7.42B |
Log In |
Log In |
Log In | Upgrade
|
| BioPharmaceuticals V&I Revenue | 1.20B | 1.06B |
Log In |
Log In |
Log In | Upgrade
|
| Rare Disease Revenue | 9.03B | 8.67B |
Log In |
Log In |
Log In | Upgrade
|
| Other Medicines Revenue | 1.00B | 1.07B |
Log In |
Log In |
Log In | Upgrade
|
| COVID-19 Revenue | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Collaboration Revenue | 1.62B | 3.14B |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 58.13B | 54.07B |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| UK Revenue | - | 4.74B |
Log In |
Log In |
Log In | Upgrade
|
| Rest of Europe Revenue | - | 11.70B |
Log In |
Log In |
Log In | Upgrade
|
| The Americas Revenue | - | 24.99B |
Log In |
Log In |
Log In | Upgrade
|
| Asia, Africa & Australasia Revenue | - | 12.64B |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Other) | 58.13B | - |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 58.13B | 54.07B |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Geography
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| UK Operating Profit | - | 2.68B |
Log In |
Log In |
Log In | Upgrade
|
| Rest of Europe Operating Profit | - | 5.92B |
Log In |
Log In |
Log In | Upgrade
|
| The Americas Operating Profit | - | 423.00M |
Log In |
Log In |
Log In | Upgrade
|
| Asia, Africa & Australasia Operating Profit | - | 976.00M |
Log In |
Log In |
Log In | Upgrade
|
| Operating Income (Other) | 12.80B | - |
Log In |
Log In |
Log In | Upgrade
|
| Operating Income (Total) | 12.80B | 10.00B |
Log In |
Log In |
Log In | Upgrade
|
Capital Expenditures by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2019 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2019 |
| UK Assets Acquired | 582.00M |
Log In |
Log In |
Log In | Upgrade
|
| Rest of Europe Assets Acquired | 2.23B |
Log In |
Log In |
Log In | Upgrade
|
| The Americas Assets Acquired | 3.93B |
Log In |
Log In |
Log In | Upgrade
|
| Asia, Africa & Australasia Assets Acquired | 1.39B |
Log In |
Log In |
Log In | Upgrade
|